Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease.
Lorenz Kocheise,Ignazio Piseddu,Joscha Vonderlin,Eric T Tjwa,Gustav Buescher,Lucy Meunier, Pia Goeggelmann, Francesca Fianchi,Jérôme Dumortier,Mar Riveiro Barciela,Tom J G Gevers,Benedetta Terziroli Beretta-Piccoli,Maria-Carlota Londoño,Sona Frankova,Thomas Roesner,Vincent Joerg,Constantin Schmidt,Fabian Glaser, Jan P Sutter,Thorben W Fründt,Ansgar W Lohse,Samuel Huber,Johann von Felden,Marcial Sebode,Kornelius Schulze Frontiers in immunology（2024）
摘要
[This corrects the article DOI: 10.3389/fimmu.2023.1326078.].
更多查看译文
AI 理解论文
溯源树
样例
